On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against ...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between ...

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...

Sales of Merck’s HPV vaccine plummeted 41% in the first quarter, as the company continues to deal with lower demand in China.

Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.

Gardasil 9 is the only HPV vaccine used in the U.S., and it’s also one of the only vaccines on the market that actually prevents cancer. That’s because HPV is behind nearly all cervical cancer cases ...

Why it matters: Investors have been particularly concerned about demand for HPV vaccine Gardasil in China, with uncertainty around pharmaceutical tariffs also weighing on shares. Gardasil's 41% ($ ...

GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1.

Sales of WELIREG increased 63%, reaching $137 million. Vaccine portfolio performance included GARDASIL sales of $1.3 billion, impacted by a 40% decline in China due to elevated channel inventories.

A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s ...